[go: up one dir, main page]

GB201701400D0 - Compound for use in medicine - Google Patents

Compound for use in medicine

Info

Publication number
GB201701400D0
GB201701400D0 GBGB1701400.2A GB201701400A GB201701400D0 GB 201701400 D0 GB201701400 D0 GB 201701400D0 GB 201701400 A GB201701400 A GB 201701400A GB 201701400 D0 GB201701400 D0 GB 201701400D0
Authority
GB
United Kingdom
Prior art keywords
medicine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1701400.2A
Other versions
GB2559162A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bradford
Original Assignee
University of Bradford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bradford filed Critical University of Bradford
Priority to GB1701400.2A priority Critical patent/GB2559162A/en
Publication of GB201701400D0 publication Critical patent/GB201701400D0/en
Priority to PCT/GB2018/050222 priority patent/WO2018138510A1/en
Publication of GB2559162A publication Critical patent/GB2559162A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1701400.2A 2017-01-27 2017-01-27 Compound for use in medicine Withdrawn GB2559162A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1701400.2A GB2559162A (en) 2017-01-27 2017-01-27 Compound for use in medicine
PCT/GB2018/050222 WO2018138510A1 (en) 2017-01-27 2018-01-26 Mebendazole for use in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1701400.2A GB2559162A (en) 2017-01-27 2017-01-27 Compound for use in medicine

Publications (2)

Publication Number Publication Date
GB201701400D0 true GB201701400D0 (en) 2017-03-15
GB2559162A GB2559162A (en) 2018-08-01

Family

ID=58462631

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1701400.2A Withdrawn GB2559162A (en) 2017-01-27 2017-01-27 Compound for use in medicine

Country Status (2)

Country Link
GB (1) GB2559162A (en)
WO (1) WO2018138510A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115721722A (en) * 2022-11-09 2023-03-03 浙江大学 Pharmaceutical composition for treating EGFR-TKI-resistant non-small cell lung cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585199A (en) * 2019-08-16 2019-12-20 华东理工大学 Application of mebendazole in preparation of medicine for treating acute T-lymphoblastic leukemia
CA3097717A1 (en) * 2020-11-02 2022-05-02 Skymount Medical Us Inc. TYROSINE KINASE IN THE TREATMENT OF CORONAVIRUS DISEASES
CN115177590A (en) * 2022-04-20 2022-10-14 南昌大学抚州医学院 Preparation method and application of mebendazole liposome
EP4537834A1 (en) * 2023-10-11 2025-04-16 Eberhard Karls Universität Tübingen (Medizinische Fakultät) Precision immunosuppression as prevention and therapy for graft-versus-host disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038022A1 (en) * 2001-03-26 2005-02-17 Unisearch Limited Method for treatment of cancer and compositions for use therein
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
US20150065526A1 (en) * 2013-09-05 2015-03-05 Emory University Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
JP2017031059A (en) * 2014-01-29 2017-02-09 学校法人慶應義塾 Cancer stem cell growth inhibitor and intracellular active oxygen accumulation inducer
US11110079B2 (en) * 2015-02-06 2021-09-07 The Johns Hopkins University Mebendazole polymorph for treatment and prevention of tumors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115721722A (en) * 2022-11-09 2023-03-03 浙江大学 Pharmaceutical composition for treating EGFR-TKI-resistant non-small cell lung cancer
CN115721722B (en) * 2022-11-09 2024-01-05 浙江大学 Pharmaceutical composition for treating EGFR-TKI resistant non-small cell lung cancer

Also Published As

Publication number Publication date
WO2018138510A1 (en) 2018-08-02
GB2559162A (en) 2018-08-01

Similar Documents

Publication Publication Date Title
IL252532A0 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL254552A0 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL247072A0 (en) Medical use
IL283335B (en) Dihydropyrimidin-2-one compounds and medical use thereof
GB201502412D0 (en) Therapeutic use
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
GB201701400D0 (en) Compound for use in medicine
ZA201701492B (en) Pyrazolothiazole compound and medicine
GB201517133D0 (en) New pharmaceutical use
SG11201608123VA (en) Pharmaceutical composition for external use
GB201506786D0 (en) Therapeutic use
GB201616880D0 (en) Compound for use in medicine
SG11201608124XA (en) Pharmaceutical composition for external use
GB201701388D0 (en) Compound for use in medicine
GB201715316D0 (en) Medicine Etc
GB201702051D0 (en) New Pharmaceutical use
GB201616767D0 (en) New pharmaceutical use
GB201601991D0 (en) Medicine
SG11201608122PA (en) Pharmaceutical composition for external use
GB201517454D0 (en) New pharmaceutical use
GB201517132D0 (en) New pharmaceutical use
GB201508611D0 (en) New pharmaceutical use
GB201508613D0 (en) New pharmaceutical use
GB201507813D0 (en) New pharmaceutical use
PH32015000070S1 (en) Medical container

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)